Published in Cardiovascular Business Week, December 14th, 2004
In 2001, Cardio acquired 26% of Estracure for CDN$2.5 million. Estracure used those funds to begin clinical trials at five sites in Canada, assessing the validity of the use of estradiol with drug-eluting stents
Cardio will acquire an additional 25% of Estracure for CDN$7.5 million bringing its ownership of Estracure to approximately 51%.
Pursuant to a conditional stock exchange agreement dated April 4, 2002 as...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cardiovascular Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.